(ionomycin)-induced arachidonatc release in human platelets. Additionally. we have shown that the degree of potcntiation by I'MA significantly increases between preincubntion periods o f I nnd 30-60 min 121, although the mechanism(s) responsible for this time-dependent enhancement remain unclcnr. I n the present study we have measured the time course o f PMA-induced protein phosphorylation and corrclatcd this with the degree of potentiation o f Ca.'+-induced arachidonatc release by PMA over a similar time period. We have also ex:imined the possibility that arachidonate release may be modulated in membranes prepared from PMAtreated platelets using radiolabelled exogenous phospholipid substrates. Free ICa, 
and 97 kDa were also phosphorylated in membrane fractions prepared from [32P]P,-labelled, PMA-treated platelets. These results imply that the enhancement of Ca"-induced arachidonate release by PKC activators may well be controlled by the PKC-mediated phosphorylation of specific platelet proteins. This hypothesis is strengthened by the observation that synergism between Ca? + -induced arachidonate release and PKC activation, and PKC-mediated protein phosphorylation were reduced by the PKC inhibitor staurosporine IS]. The identification of these proteins and their potential function in controlling arachidonic acid release via modulation of PLAz activity and/or phospholipid substrate availability is currently under investigation. Possible candidates for PKC action include the anti-PLA, proteins the lipocortins (35-40 kDa and 60-65 kDa), and calelectrin (67 kDa).
As an initial step towards identifying the mechanisms involved in synergistic enhancement of arachidonate libcration by PKC, we went on to examine PLA2-induced arachidonate release from crude platelet membranes. PLA, activity was measured in membranes prepared from resting and PMA-treated platelets (60 n M , 1 0 min unstirred) using a modification of the procedure employed by Jelsema 161. Briefly, platelet membranes (100 pug) were incubated (37°C) in Tris/HCI buffer (30 mM, pH 8.0) containing 40 mMMgCI,, 1 mM-EGTA, varying free Ca" concentrations and 22 p~-l-~tearoyl-2-[~H]arachidonylPtdCho ( S O mCi/mmol; Amersham International) or 24 PM-I-~tearoyl-2-['~CIarachi-donylphosphatidylethanolamine (PtdEth; 52.6 mCi/mmol; New England Nuclear). Reactions were terminated after 90 min with 3 ml of Dole's reagent (isopropyl alcohol/nheptane/l N H,SO,, 40/10/1) and free 3H-or lJC-labelled arachidonate in the heptane phase were quantified by liquid scintillation counting. In control membranes (vehicletreated), PLA, activity was enhanced by Ca2+ concentrations exceeding 5 p~ in a dose-dependent manner (Fig. 1 ) . Furthermore, Ca? +-induced PLA, activity was significantly elevated in membranes prepared from PMA-stimulated platelets with maximal stimulation occurring at 1 mM-Ca?'. Exposure to Ca2+ levels greater than 1 mM led to inhibition of arachidonate release (data not shown). In marked contrast, release of ["Clarachidonate from [ "CIPtdEth was not detected under identical assay conditions in thc absence o r presence of Ca?+ in either untreated or PMA-stimulated membranes. Collectively, our results (i) have confirmed that PtdCho is the major substrate for PLA, in human plateletswhether PtdEth is also subject t o small but significant PLA,-mediated hydrolysis, as suggested in earlier studies 17. XI. will be addressed in future studies using PLA, purified from cytosolic and particulate compartments; (ii ) have demonstrated that PKC-mediated enhancement of arachidonatc release from exogenous PtdCho can be monitored in a ccllfree system and that control by PKC may show substrate selectivity; and (iii) suggest that arachidonate rclcase and the subsequent generation of eicosanoid products in platelets may be critically dependent o n PKC-mediated protein phosphorylation.
('hem. 260 Although several recent studies 11-31 have described inhibitory effects o f agents elevating cyclic GMP (cg. nitroprusside (NP), nitric oxide) on platelet activation responses, a detailed investigation of the effects of these agents on different platelet processes has not been carried out. As a consequence, the primary site of inhibitory action o f these agents still remains to be identified. In the present study, we have examined the effects of NP and 8 -h o m o cyclic GMP on platelet aggregation and various internal processes such as phospholipase and protein kinasc activation, in an attempt to identify the principal mechanism by which raised cyclic GMP levels cause inhibition of platelet function.
Washed human platelets (2-4 x 10H/ml) rcsuspended in Hepes/Tyrode buffer (pH 7.4) wcrc prcloadcd with markers to study various reactions. cg. 1 "C Iscrotonin. I.'H larachidonic acid (AA), I"P]P, and quin 2 as described previously 141. Platelets werc pretreated with I 0 pM-indomethacin for all experiments to avoid the effects of cyclo-oxygenase products, and additionally pretreated with 250 p~-p h e n idone for experiments on A A release t o inhibit lipoxygcnase activity as well. Table 1 [ lJC]serotonin release: thrombin control. 59.6 + 3.6%; I00 ,uM-NP+ thrombin. 46.9 + S.h'%,; PA formation: thrombin control. 534 + 66%; 100 ,uM-NP+ thrombin. 555 + 67% of
